TYTiecheng Yu

Tiecheng Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiecheng Yu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Gu

    Department of Orthopedics First Hospital of Jilin University changchun jilin China

    11 shared publications
  • Jiangbi Li

    Department of Orthopedics First Hospital of Jilin University changchun jilin China

    11 shared publications
  • Xiaoping Xie

    Department of Sports Medicine, Hubei Sports Medicine Center, Wuhan Fourth Hospital

    11 shared publications
  • Ke Zhang

    Department of Orthopedics First Hospital of Jilin University changchun jilin China

    10 shared publications
  • Zhenjiang Sui

    Department of Orthopedics First Hospital of Jilin University changchun jilin China

    9 shared publications
  • Yang Sun

    Department of Orthopedics, Orthopedics Center, First Hospital of Jilin University, Jilin University, Changchun, China

    6 shared publications

Latest Publications

  • Open Access

    GelMA hydrogel enhances diabetic wound healing by delivering shock wave-preconditioned BMSC-derived small extracellular vesicles

    by Rongqi Zhou, Xiaoping Xie, Xudong Li, Songqi Bi, Zhixing Yan, Xiaoyang Zhou, Fanxu Wang, Tiecheng Yu

    Introduction: Diabetic foot ulcers (DFUs) are chronic, hard-to-heal wounds characterized by impaired angiogenesis, persistent inflammation, and defective extracellular matrix remodeling. Bone marrow mesenchymal stem cell-derived small extracellular vesicles (BMSC-sEVs) hold promise for cell-free therapy; however, their therapeutic efficacy is limited by insufficient reparative bioactivity and rapid local clearance. This study aimed to enhance the intrinsic therapeutic potential of BMSC-sEVs through shock wave preconditioning and improve their local retention and sustained delivery using gelatin methacryloyl (GelMA) hydrogel. Methods: BMSCs were preconditioned with shock waves, and the resulting small extracellular vesicles (SW-sEVs) were isolated and characterized. Their angiogenic and immunomodulatory effects were evaluated using human umbilical vein endothelial cells (HUVECs) and RAW264.7 macrophages. Proteomic analysis and Western blotting were performed to investigate potential underlying mechanisms. SW-sEVs were subsequently incorporated into a 15% GelMA hydrogel, and the resulting delivery system was characterized. Its therapeutic efficacy was evaluated in a streptozotocin (STZ)-induced hyperglycemic rat wound model. Results: Shock wave preconditioning did not alter the typical morphology, particle size distribution, or marker protein expression of BMSC-sEVs. Compared with sEVs derived from untreated BMSCs, SW-sEVs significantly enhanced HUVEC proliferation, migration, and tube formation, accompanied by increased VEGFA and CD31 expression. SW-sEVs also suppressed pro-inflammatory macrophage activation, promoted a reparative macrophage phenotype, and reduced the expression of pro-inflammatory factors. Proteomic analysis revealed alterations in sEV protein cargo, with differentially expressed proteins enriched in inflammation-related pathways, including NF-κB signaling. Western blotting further demonstrated reduced phosphorylation of p65 and IκBα following SW-sEV treatment. The 15% GelMA hydrogel exhibited an interconnected porous structure, favorable cytocompatibility, structural stability, and sustained SW-sEV release. In vivo, GelMA-SW-sEVs significantly accelerated diabetic wound healing, enhanced neovascularization and M2 macrophage polarization, reduced local inflammation, and improved re-epithelialization, collagen deposition, and tissue remodeling. Discussion: Shock wave preconditioning enhances the angiogenic and immunomodulatory activities of BMSC-sEVs, potentially through modulation of NF-κB-related inflammatory signaling. Combined with sustained local delivery using GelMA hydrogel, SW-sEVs demonstrate promising therapeutic potential as a cell-free strategy for diabetic wound repair.

  • Open Access

    Early Radial Extracorporeal Shockwave Stimulation on Proximal Tibial Circular Osteotomy Site Enhanced Heterotopic Skin Wound Healing via Small Extracellular Vesicles

    by Xiaoping Xie, Songqi Bi, Bang Su, Rongqi Zhou, Xudong Li, Zhixing Yan, Xiaoyang Zhou, Fanxu Wang, Tiecheng Yu

    Wound healing represents a complex biological process necessitating innovative therapeutic approaches, particularly for chronic wounds such as diabetic foot ulcers (DFUs). Inspired by the regenerative effects of tibial bone transport for DFUs, we explored whether radial extracorporeal shockwave therapy (rESWT) at the tibial annular osteotomy site (TOE) could enhance wound healing in rats. We found that TOE accelerated dorsal foot wound healing via small extracellular vesicles (sEV). This sEVs showed strong regenerative effects and modulated macrophage polarizations in vitro and in vivo. Single‐cell sequencing revealed mesenchymal stem cells as the likely sEV source, with rESWT triggering sEV release through ATP/P2X7R/p38MAPK pathway. Proteomic analysis identified five differentially expressed proteins in sEVs, with Thrombospondin 1 (Thbs1)‐enhanced sEVs enhancing wound healing by promoting IL4‐induced M2 macrophage polarization. This innovative approach represents a promising alternative strategy for wound management, with potential for future DFU treatment.


  • Open Access

    Biomechanical evaluation of percutaneous compression plate and femoral neck system in Pauwels type III femoral neck fractures

    by Xiaoping Xie, Songqi Bi, Qingxu Song, Qiong Zhang, Zhixing Yan, Xiaoyang Zhou, Tiecheng Yu

    Background: The optimal treatment for Pauwels type III femoral neck fractures remains contentious. We aim to compare the biomechanical properties of three inverted cannulated compression screw (ICCS), femoral neck system (FNS), and percutaneous compression plate (PCCP) to determine which offers superior stability for unstable femoral neck fractures. Materials and methods: Finite element analysis and artificial bone models were used to establish Pauwels III femoral neck fracture models. They were divided into ICCS, FNS, and PCCP groups based on respective internal fixation assemblies. The models were subjected to vertical axial loads (2100 N) and torsional forces (10 N × mm) along the femoral neck axis in the finite element analysis. The primary outcomes such as the Z axis fragmentary displacements, as well as displacements and the von Mises stress (VMS) distributions of internal fixations, were analyzed. Additionally, the artificial bones were subjected to progressively increasing vertical axial pressures and torsional moments at angles of 2°, 4°, and 6°, respectively. The vertical displacements of femoral heads and the required torque values were recorded. Results: Finite element analysis revealed that under single-leg stance loading, the maximum Z-axis fragmentary displacements were 5.060 mm for ICCS, 4.028 mm for FNS, and 2.796 mm for PCCP. The maximum displacements of internal fixations were 4.545 mm for ICCS, 3.047 mm for FNS, and 2.559 mm for PCCP. Peak VMS values were 512.21 MPa for ICCS, 242.86 MPa for FNS, and 413.85 MPa for PCCP. Under increasing vertical loads applied to the artificial bones, the average vertical axial stiffness for the ICCS, FNS, and PCCP groups were 244.86 ± 2.84 N/mm, 415.03 ± 27.10 N/mm, and 529.98 ± 23.08 N/mm. For the torsional moment tests, the PCCP group demonstrated significantly higher torque values at 2°, 4°, and 6° compared with FNS and ICCS, with no significant difference between FNS and ICCS (P > 0.05). Conclusions: Finite element analysis and artificial bone models indicated that PCCP offers the best compressive and rotational stability for fixing Pauwels type III femoral neck fractures, followed by FNS and then ICCS. No significant difference in rotational resistance was observed between FNS and ICCS in synthetic bones. Level of Evidence Level 5.


  • Open Access

    Silicone rubber sealed channel induced self-healing of large bone defects: Where is the limit of self-healing of bone?

    by Feng Gu, Ke Zhang, Wan-An Zhu, Zhenjiang Sui, Jiangbi Li, Xiaoping Xie, Tiecheng Yu


  • Open Access

    Risk of osteoporosis in patients treated with direct oral anticoagulants vs. warfarin: an analysis of observational studies

    by Yumeng Liu, Xiaoping Xie, Songqi Bi, Qiong Zhang, Qingxu Song, Yang Sun, Tiecheng Yu

    Aims: Evidence on the association between the risk of new-onset osteoporosis and oral anticoagulants remains controversial. We aimed to compare the risk of osteoporosis associated with the use of direct oral anticoagulants (DOACs) with that associated with warfarin use.Methods: Studies published up to 15 March 2023 that investigated the association between the use of DOACs and warfarin and the incidence of osteoporosis were identified by online searches in PubMed, Embase, the Cochrane Library, and Web of Science conducted by two independent investigators. Random-effects or fixed-effect models were employed to synthesize hazard ratios (HRs)/relative ratios (RRs) with 95% confidence intervals (CIs) for estimating the risk of osteoporosis correlated with DOAC and warfarin prescriptions (PROSPERO No. CRD42023401199).Results: Our meta-analysis ultimately included four studies involving 74,338 patients. The results suggested that DOAC use was associated with a significantly lower incidence of new-onset osteoporosis than warfarin use (pooled HR: 0.71, 95% CI: 0.57 to 0.88, p < 0.001, I2: 85.1%). Subanalyses revealed that rivaroxaban was associated with a lower risk of osteoporosis than both warfarin and dabigatran. In addition, DOACs were associated with a lower risk of developing osteoporosis than warfarin in both male and female patients, in patients with atrial fibrillation (AF), and in patients who underwent therapy for > 365 days.Conclusion: DOAC users experienced a lower incidence of osteoporosis than warfarin users. This study may give us insight into safe anticoagulation strategies for patients who are at high risk of developing osteoporosis.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023401199.


  • Open Access

    Gamma Nail Combined with One Cannulated Compression Screw Fixation for Treating Pauwels Type III Femoral Neck Fractures in Young and Middle‐Aged Adults: Clinical Follow‐Up and Biomechanical Studies

    by Qiangqiang Wen, Feng Gu, Zilong Su, Ke Zhang, Xiaoping Xie, Jiangbi Li, Zhenjiang Sui, Tiecheng Yu

    Objective: Recently, some clinical studies have reported the use of an intramedullary nailing system for treating unstable femoral neck fractures or femoral neck fractures combined with femoral shaft fractures in young adults, and the results have indicated certain advantages. However, no study has investigated the mechanical properties of this method. We aimed to evaluate the mechanical stability and clinical efficacy of the Gamma nail combined with one cannulated compression screw (CCS) fixation for treating Pauwels type III femoral neck fracture in young and middle‐aged adults.Methods: This study consists of two parts: a clinical retrospective study and randomized controlled biomechanical test. Twelve adult cadaver femora were used to test and compare the biomechanical properties among three fixation methods: three parallel CCS (group A), Gamma nail (group B), and Gamma nail combined with one cannulated compression screw (group C). The single continuous compression test, cyclic load test, and ultimate vertical load test were used to evaluate the biomechanical performance of the three fixation methods. We also conducted a retrospective study of 31 patients with Pauwels type III femoral neck fractures, including 16 patients with fractures fixed with three parallel CCS (CCS group) and 15 patients with fractures fixed with Gamma nail combined with one CCS (Gamma nail + CCS group). The patients were followed up for at least 3 years, and all were evaluated for surgical time (from skin incision to closure), surgical blood loss, hospital stay, and the Harris hip score.Results: In mechanical experiments, we have found that the mechanical advantages of Gamma nail fixation are not as good as those of conventional CCS fixation. However, the mechanical properties of Gamma nail fixation combined with one cannulated screw perpendicular to the fracture line are much better than those of Gamma nail fixation and CCS fixation. No significant difference was found in the incidence of femoral head necrosis and nonunion between the CCS and Gamma nail + CCS groups. Moreover, there was no statistically significant difference in the Harris hip scores between the two groups. One patient in the CCS group showed significant withdrawal of cannulated screws at 5 months after surgery, whereas in the Gamma nail + CCS group, all patients, including those with femoral neck necrosis, showed no loss of stability of the fixation.Conclusion: Among the two fixation methods evaluated in this study, Gamma nail combined with one CCS fixation showed better biomechanical properties and may reduce complications associated with unstable fixation devices.


  • Open Access

    Non-antibiotic strategies for prevention and treatment of internalized Staphylococcus aureus

    by Jiangbi Li, Qiangqiang Wen, Feng Gu, Lijuan An, Tiecheng Yu

    Staphylococcus aureus (S. aureus) infections are often difficult to cure completely. One of the main reasons for this difficulty is that S. aureus can be internalized into cells after infecting tissue. Because conventional antibiotics and immune cells have difficulty entering cells, the bacteria can survive long enough to cause recurrent infections, which poses a serious burden in healthcare settings because repeated infections drastically increase treatment costs. Therefore, preventing and treating S. aureus internalization is becoming a research hotspot. S. aureus internalization can essentially be divided into three phases: (1) S. aureus binds to the extracellular matrix (ECM), (2) fibronectin (Fn) receptors mediate S. aureus internalization into cells, and (3) intracellular S. aureus and persistence into cells. Different phases require different treatments. Many studies have reported on different treatments at different phases of bacterial infection. In the first and second phases, the latest research results show that the cell wall-anchored protein vaccine and some microbial agents can inhibit the adhesion of S. aureus to host cells. In the third phase, nanoparticles, photochemical internalization (PCI), cell-penetrating peptides (CPPs), antimicrobial peptides (AMPs), and bacteriophage therapy can effectively eliminate bacteria from cells. In this paper, the recent progress in the infection process and the prevention and treatment of S. aureus internalization is summarized by reviewing a large number of studies.


  • Open Access

    Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis

    by Yang Sun, Yue Li, Jiangbi Li, Xiaoping Xie, Feng Gu, Zhenjiang Sui, Ke Zhang, Tiecheng Yu

    Aim: Evidence on the efficacy of combination treatment of teriparatide and denosumab for osteoporosis remains controversial. We aim to compare the efficacy between the combination treatment and monotherapy among patients with postmenopausal osteoporosis.Methods and results: We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science up to 26 January 2022, for relevant studies. This meta-analysis reviewed all randomized controlled trials (RCTs) that reported on the combination treatment of teriparatide and denosumab in patients with postmenopausal osteoporosis. The articles were examined individually by two reviewers, and the relevant data was extracted. We combined weighted mean difference (WMD) for bone mineral density (BMD) using random- or fixed- effect models and conducted subgroup analyses. Sensitivity analyses were performed, and possible publication bias was also assessed. Overall, combination treatment enhanced the mean percent change of bone mineral density in lumbar spine than monotherapy (WMD = 2.91, 95%CI: 1.983.83; p = 0.00). And, combination treatment has been beneficial for enhancing the mean percent change of BMD in hip (WMD = 3.19, 95%CI: 2.25∼4.13; p = 0.00). There was no significant difference between combination treatment and monotherapy in terms of the adverse events (RR = 0.81, 95%CI: 0.45∼1.45; p = 0.472).Conclusion: The meta-analysis indicates that combination treatment led to greater BMD at the lumbar spine and hip in comparison to monotherapy, without an increased incidence of adverse events.Systematic Review Registration: (https://inplasy.com/), identifier (Inplasy Protocol 2734).


  • Open Access

    Effects of Bisphosphonates Treatments in Osteopenic Older Women: A Systematic Review and Meta-Analysis

    by Jiangbi Li, Yang Sun, Zhuo Chen, Xiaoping Xie, Feng Gu, Songqi Bi, Tiecheng Yu

    Aims: To review the effects of bisphosphonates on bone density, fractures, and bone markers in osteopenic older women.Methods: Relevant articles published before February 2022 were searched in PubMed, EMBASE, and the Cochrane Library. All randomized controlled trials that reported incident fractures, bone mineral density (BMD), bone markers, or adverse events with bisphosphonates in osteopenic older women were included. The quality of included studies was assessed using the Cochrane Risk of Bias tool. The risk ratios (RRs) for fractures, net percent change in bone mineral density and differences in bone markers were calculated using a meta-analysis.Results: A total of 11 studies were included in our meta-analysis. Bisphosphonates significantly increased the percent changes in the lumbar spine BMD (WMD, 5.60; 95% CI, 4.16–7.03; I2 = 93.6%), hip BMD (WMD, 4.80; 95% CI, 2.93 to 6.66; I2 = 97.1%), total body BMD (WMD, 3.24; 95% CI, 2.12–4.35; I2 = 90.9%), femoral neck BMD (WMD, 4.02; 95% CI, 1.70–6.35; I2 = 91.8%) and trochanter BMD (WMD, 5.22; 95% CI, 3.51–6.93; I2 = 83.6%) when compared to placebo. Zoledronate was associated with a great treatment effect on fragility fracture (RR, 0.63; 95% CI, 0.50–0.79), clinical vertebral fracture (RR, 0.41; 95% CI, 0.22–0.76), and radiographic vertebral fracture (RR, 0.60; 95% CI, 0.27–1.35) compared to placebo. Meanwhile, alendronate was also associated with beneficial effects on fragility fracture (RR, 0.40; 95% CI, 0.15–1.07), clinical vertebral fracture (RR, 0.46; 95% CI, 0.17–1.24), and radiographic vertebral fracture (RR, 0.64; 95% CI, 0.38–1.09). In addition, the use of bisphosphonates reduced the concentration of procollagen type I N-terminal propeptide (PINP) and C-terminal telopeptide of type I collagen (CTX) over placebo by 15.79 (95% CI, −18.92 to −12.66; I2 = 28.4%), −0.23 (95% CI, −0.35 to −0.10; I2 = 91.3%), respectively. Although there was insufficient evidence to determine their safety, these bisphosphonates may have an effect on cancer, cardiac events, and mortality in osteopenic older women.Conclusion: All bisphosphonates examined were associated with beneficial effects on fractures, BMD, and bone markers in women with osteopenia. Further randomized controlled trials are necessary to clarify the safety of bisphosphonates in women with osteopenia.